Sanofi (EURONEXT: SAN and NYSE: SNY) ranked third among twenty pharmaceutical companies on the 2012 Access to Medicine Index (ATM

[column width=”360px” padding=”20px”]We are in the midst of third quarter earnings reports, and they show with stark detail what the

[column width=”360px” padding=”20px”]The supercharged race to get new treatments into the lucrative market for treating rheumatoid arthritis (RA) appeared to